Journal
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
Volume 17, Issue 5, Pages -Publisher
SPRINGER
DOI: 10.1007/s11910-017-0751-0
Keywords
Atypicalparkinsonism; MSA; Alpha-synuclein; Oligodendrocyte
Categories
Funding
- E-Rare-2, the ERA-Net for Research on Rare Diseases [ANR-14-RARE-0001-01]
- FP7 under European Union Seventh Framework Program [602999]
Ask authors/readers for more resources
Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder that is characterized by a variable combination of parkinsonism, cerebellar impairment, and autonomic dysfunction. Some symptomatic treatments are available while neuroprotection or disease-modification remain unmet treatment needs. The pathologic hallmark is the accumulation of aggregated alpha-synuclein (a-syn) in oligodendrocytes forming glial cytoplasmic inclusions, which qualifies MSA as synucleinopathy together with Parkinson's disease and dementia with Lewy bodies. Despite progress in our understanding of the pathogenesis of MSA, the origin of a-syn aggregates in oligodendrocytes is still a matter of an ongoing debate. We critically review here studies published in the field over the past 5 years dealing with pathogenesis, genetics, clinical signs, biomarker for improving diagnostic accuracy, and treatment development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available